TipRanks
Advertisement
Advertisement

CANF Stock Latest News

Can-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant
Company AnnouncementsCan-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant
11d ago
6K
CANF
Can-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs
PremiumCompany Announcements
Can-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs
12d ago
6K
CANF
Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing
PremiumCompany Announcements
Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing
17d ago
6K
CANF
Can-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline
PremiumCompany Announcements
Can-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline
18d ago
6K
CANF
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
PremiumThe Fly
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
18d ago
CANF
Can-Fite Flags Longer Survival in Phase III Liver Cancer Trial, Eyes Earlier Interim Analysis
PremiumCompany AnnouncementsCan-Fite Flags Longer Survival in Phase III Liver Cancer Trial, Eyes Earlier Interim Analysis
18d ago
6K
CANF
Can-Fite BioPharma files $100M mixed securities shelf
Premium
The Fly
Can-Fite BioPharma files $100M mixed securities shelf
23d ago
CANF
Can-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer
Premium
Company Announcements
Can-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer
1M ago
6K
CANF
Can-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways
PremiumCompany Announcements
Can-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways
1M ago
6K
CANF
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
PremiumThe Fly
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
2M ago
CANF
Can-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome
PremiumCompany Announcements
Can-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome
2M ago
6K
CANF
Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation
PremiumCompany Announcements
Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation
2M ago
6K
CANF
Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer
PremiumCompany AnnouncementsCan-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer
2M ago
6K
CANF
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
Premium
The Fly
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
2M ago
CANF
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
Premium
Company Announcements
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
3M ago
6K
CANF
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
PremiumThe Fly
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
3M ago
CANF
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
PremiumThe Fly
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
3M ago
CANF
Can-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial
PremiumCompany Announcements
Can-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial
3M ago
6K
CANF
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
PremiumThe Fly
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
3M ago
CANF
Can-Fite BioPharma Wins Japanese Patent for Namodenoson’s Anti-Obesity Technology
PremiumCompany AnnouncementsCan-Fite BioPharma Wins Japanese Patent for Namodenoson’s Anti-Obesity Technology
3M ago
6K
CANF
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
Premium
The Fly
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
3M ago
CANF
Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
Premium
Company Announcements
Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
3M ago
6K
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >